Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
The Perelman School of Medicine at the University of Pennsylvania and the March of Dimes Foundation announce the launch of a new $10 million Prematurity Research Center here.
The March of Dimes will invest $10 million during the next five years to create a transdisciplinary center conducting team-based research, led by physicians and researchers at the Hospital of the University of Pennsylvania and The Children’s Hospital of Philadelphia, to discover the unknown causes of preterm birth and develop new strategies to prevent it. This March of Dimes Prematurity Research Center at the University of Pennsylvania is part of a “medical Manhattan Project” of five such centers in the United States created by the foundation since 2011.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/65164-march-of-dimes-march-for-babies-2014/
The thinking that diet does not affect acne is a falsehood perpetuated by that part of the medical industry that is trying to protect their livelihood of dispensing drugs. The AMA has established that the only way to deal with acne is through the use of medication. They say there is no evidence to support the idea that diet causes acne.
Today, WebMD released My Abuelita Told Me, a new five-part video series developed in partnership with Dr. Juan Rivera (“Dr. Juan”), a board-certified internist and cardiologist, who is well-known for his best-selling books and regular appearances on broadcast television. My Abuelita Told Me explores the reliability of the various home remedies, beliefs and established practices that beloved abuelitas (a.k.a. grandmas) have passed down through the generations, and Dr. Juan clarifies what is or isn’t accurate using medical science.
To view the multimedia release go to:
https://www.multivu.com/players/English/7579758-webmd-my-abuelita-told-me-bilingual-video-series/
Today, WebMD released In Their Own Words: Moving Beyond Migraine with Robin Roberts, a new five-part video series that sheds light on the debilitating nature of migraine and the impact it has on all aspects of a sufferer’s personal and professional life.
To learn more about treatments and the individuals featured in In Their Own Words: Moving Beyond Migraine with Robin Roberts, visit: to www.webmd.com/insidemigraines.
Moving Beyond Migraine follows the lives of Jennifer, a public school administrator who has lived with intense migraine headaches for over 20 years; Kate, a 20-year-old college student with debilitating migraines that have run in her family for generations; Melanie, whose intense migraine condition has altered the dynamics of her nine year marriage; and Lynn, who after suffering from migraine for 50 years, shares how a clinical trial for a new treatment called CGRP targeted therapy is finally providing her with some relief.
To view the multimedia release go to:
https://www.multivu.com/players/English/7579759-robin-roberts-moving-beyond-migraine/
Medical transcription outsourcing streamlines research by converting audio into accurate text, boosting efficiency, compliance, and enhancing collaboration.
On World Mental Health Day, Janssen has announced the results of a pan-European research project: ‘Talking About Treatment in Schizophrenia: A Patient and Carer Survey’. The survey of 166 adults living with schizophrenia and 468 carers was conducted by the independent market research agency, Fieldwork International (part of Ipsos MORI), and explored awareness, feelings and preferences regarding treatment.
The survey, conducted across 12 countries in Europe (Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Russia, Spain, Sweden, Switzerland and the UK), highlighted key factors affecting the peace of mind for carers, such as the impact of the condition on day‑to-day life, potential relapse/hospitalisation and getting support beyond medication. 94% stated they reminded the person they care for to take their medication and for 49% this happens often.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7947151-janssen-survey-carers-adults-schizophrenia/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Professor Lionel Tarassenko, CBE, Head of Engineering at the University of Oxford and Fellow of the Royal Academy of Engineering and the Academy of Medical Sciences, has joined a panel of internationally recognised experts for the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
As the worlds of science and technology come together, the 2015 Astellas Innovation Debate, organised and funded by Astellas, will discuss recent breakthroughs in genetic medicine and smart technology, and what they mean for our health.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7432051-lionel-tarassenko-astellas-debate/
Strategic Partners, Inc., the leader in the manufacturing and marketing of medical apparel, lab wear, footwear and accessories, today announced the launch of its next generation of medical apparel: scrubs, lab wear and accessories protected with CERTAINTY™ antimicrobial technology.
On a daily basis, many healthcare professionals are exposed to unwanted bacteria on their clothing. CERTAINTY antimicrobial technology can provide more fabric protection than traditional scrubs, giving healthcare professionals the freedom to perform their duties in comfortable, fashion-inspired clothing.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7458151-strategic-partners-certainty/
Oro Valley Audiology
2542 E Vistoso Commerce Loop Rd, Tucson, AZ 85755, USA
(520) 825-4770
http://hearintucson.com
https://www.google.com/maps?cid=7471816986561274177
https://www.google.com/search?q=Oro+Valley+Audiology&kponly&kgmid=/g/1thx4hd3
As the name suggests, and audiologist is a health-care professional who concentrates on the medical diagnoses, recognition, tracking and treatment of conditions of the auditory and vestibular parts of the ear. These specialists dispense hearing aids, manage and fix up hearing problems and evaluate candidacy for cochlear implants. An audiologist helps style and carry out individual and industrial hearing safety programs, newborn hearing screening programs, and school hearing screening programs.
Audiologists have training in anatomy and physiology, hearing aids, cochlear implants, electrophysiology, acoustics, psychophysics, neurology, vestibular function and evaluation, balance disorders, therapy and indication language. Unfortunately, hearing loss is prevalent throughout the U.S.
Hunova, the first robotic gym for the rehabilitation and functional motor sense evaluation of lower limbs and trunk, has been officially launched in Genoa, Italy. The first 30 robots will be available from June in Europe and the USA. The technology was developed and patented at the IIT laboratories and has been launched on the market thanks to a 10 million euro investment from entrepreneur Sergio Dompè.
Hunova is a programmable robotic medical device that allows professionals in the geriatrics, neurology and sport rehabilitation field to cure and predict many neurological and orthopedic conditions. There are two main competitive advantages of this technology: Hunova is able to collect a significant amount of data on biomechanics, constantly monitoring the patient’s progress. Secondly, it provides direct support to the patient through a guiding robotic system, offering a wide range of rehabilitation protocols in the form of video games. It consists of two electromechanical platforms equipped with sensors, characterized by two degrees of freedom (feet and seat level). The device integrates the force sensors to adjust the interaction with the patient and a wireless sensor, which is placed on the patient’s trunk, allowing the physiotherapist to check the movement of the torso.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8108951-iit-movendo-launch-robot-hunova/
